This finding indicates that hyperprolactinemia in persons with schizophrenia is not solely secondary to dopamine blockades by antipsychotics, but it reflects the potential intrinsic mechanism of the dopamine–prolactin pathway, which might contribute to both schizophrenia and metabolic syndrome [102,146]. Here, PRL is linked to metabolic syndrome.